Generation Bio Co. Common Stock(GBIO)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $3.00 – $6.95
- YTD
- +3.03%
- IV Rank (30D)
- 0
- Straddle Price
- $4.65
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.0B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.0B
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selec…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +3.42% | 6 |
| Feb | -3.00% | 6 |
| Mar | +13.17% | 5 |
| Apr | -0.81% | 5 |
| May | -9.44% | 5 |
| Jun | +2.67% | 6 |
| Jul | +4.70% | 6 |
| Aug | +10.90% | 6 |
| Sep | -3.67% | 6 |
| Oct | -21.96% | 6 |
| Nov | +8.97% | 6 |
| Dec | -17.77% | 6 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-07 | After-Close | 70.95% | 8.11% | 0.11x | Within |
| 2024-11-06 | Pre-Market | 84.47% | 9.59% | 0.11x | Within |
| 2025-03-13 | Pre-Market | 757.01% | 2.67% | 0.00x | Within |
| 2025-05-07 | Pre-Market | 523.35% | 4.74% | 0.01x | Within |
| 2025-08-12 | Pre-Market | 120.05% | 2.72% | 0.02x | Within |
| 2025-11-05 | Pre-Market | 90.48% | 1.14% | 0.01x | Within |
- IV Rank (30D)
- 0
- IV Rank (7D)
- 0
- Avg IV
- 0.0%
- Straddle (30D)
- $4.65
- Straddle (7D)
- $4.65
- P/C Volume
- 0.00
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.32
- Correlation (SPY)
- 13.4%
- R²
- 0.02
- Ann. Volatility
- 108.6%
- SPY Volatility
- 11.0%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Ronald Harold Wilfred Cooper | Director | U | −950 | — | EDGAR | |
| 2026-02-09 | Anthony G. Quinn | Director | U | −37,211 | — | EDGAR | |
| 2026-02-09 | Yalonda Howze | INTERIM CEO AND PRESIDENT | U | −3,759 | — | EDGAR | |
| 2026-02-09 | Gustav Christensen | Director | U | −13,142 | — | EDGAR | |
| 2026-02-09 | Catherine Stehman-Breen | Director | U | −4,752 | — | EDGAR | |
| 2026-02-09 | GEOFF MCDONOUGH | Director | U | −188,638 | — | EDGAR | |
| 2026-02-09 | Kevin John Conway | CHIEF FINANCIAL OFFICER | U | −2,072 | — | EDGAR | |
| 2026-02-09 | Dannielle Appelhans | Director | U | −1,999 | — | EDGAR | |
| 2026-02-09 | Atlas Venture Associates X, LLC | 10%+ Owner | U | −4,967,676 | — | EDGAR | |
| 2026-02-09 | JEFFREY M JONAS | Director | Disp (D) | −24,366 opt | — | EDGAR | |
| 2026-02-09 | Donald William Nicholson | Director | U | −21,357 | — | EDGAR | |
| 2026-02-09 | Jason P Rhodes | Director | U | −827,946 | — | EDGAR | |
| 2026-02-09 | Charles A Jr Rowland | Director | U | −53,475 | — | EDGAR | |
| 2026-02-04 | GEOFF MCDONOUGH | Director | Mixed | +1,032 | $5.64 | -$3.1K | EDGAR |
| 2026-02-04 | Yalonda Howze | INTERIM CEO & PRESIDENT | Mixed | +1,178 | $5.64 | -$2.8K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | ATLAS VENTURE ASSOCIATES X, L.P. | 10%+ Owner | 9,111,939 | $48.66M | -$14.46M | 2 | 2021-04-14 |
| 2 | Atlas Venture Fund X, L.P. | 10%+ Owner | 8,278,876 | $44.21M | $0 | 4 | 2021-09-21 |
| 3 | Atlas Venture Opportunity Fund I, L.P. | 10%+ Owner | 7,111,939 | $37.98M | -$8.24M | 1 | 2021-09-29 |
| 4 | Thomas G. Jr. Roberts | 10%+ Owner | 3,437,638 | $18.36M | $76.00M | 1 | 2020-06-17 |
| 5 | William Seybold | 10%+ Owner | 3,437,638 | $18.36M | $30.40M | 1 | 2020-06-17 |
| 6 | Artal Group S.A. | 10%+ Owner | 2,814,191 | $15.03M | $136.80M | 1 | 2020-06-18 |
| 7 | Eli Casdin | 10%+ Owner | 1,611,215 | $8.60M | $24.70M | 1 | 2020-06-18 |
| 8 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10%+ Owner | 1,012,546 | $5.41M | $20.90M | 1 | 2020-06-18 |
| 9 | DEERFIELD PARTNERS, L.P. | 10%+ Owner | 961,215 | $5.13M | $17.10M | 1 | 2020-06-16 |
| 10 | Mark D. Angelino | CHIEF OPERATING OFFICER | 516,583 | $2.76M | -$432.7K | 3 | 2021-01-20 |
| 11 | Douglas Kerr | CHIEF MEDICAL OFFICER | 385,628 | $2.06M | -$1.55M | 16 | 2024-01-31 |
| 12 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 247,319 | $1.32M | -$2.90M | 32 | 2024-10-17 |
| 13 | Matthew Norkunas | CHIEF FINANCIAL OFFICER | 56,659 | $302.6K | $0 | 16 | 2024-10-17 |
| 14 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 49,164 | $262.5K | -$559.1K | 17 | 2024-01-31 |
| 15 | Phillip Samayoa | CHIEF SCIENTIFIC OFFICER | 14,172 | $75.7K | -$30.0K | 20 | 2025-10-17 |
| 16 | Antoinette Paone | CHIEF OPERATING OFFICER | 3,705 | $19.8K | -$128.7K | 27 | 2025-10-17 |
| 17 | Atlas Venture Associates Opportunity I, LLC | 10%+ Owner | 616 | $3.3K | -$21.75M | 2 | 2021-06-28 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.